Research Use Disclaimer Retatrutide (RETA-20) 111mg research peptide is intended strictly for laboratory research and analytical purposes only
Most metabolic peptides target one receptor
Bariatric Surgery: Patients may lose up to 60% of excess weight six months after surgery and 77% of excess weight as early as 12 months after surgery
A notable research effort, known as the STEP (Semaglutide GLP-1 Treatment Effect in People with Obesity) trial, revealed that participants taking Semaglutide GLP-1 achieved an average weight reduction of around 15% of their starting body weight within 68 weeks, unlike those taking a placebo
The company publishes available lab reports for its listed products and updates documentation as new batch information becomes available
"Perhaps doses that achieve modest weight loss but robust anti-inflammatory and vascular benefits might be appropriate for some indications, while maximum-tolerated doses remain appropriate for obesity," says Nadolsky